Reports Q2 revenue $106.4M, consensus $105.01M. “As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow. Accolade is proving the scalability and profitability of a business model and strategy that is fundamentally designed to improve the lives of millions of people and their families. Our focus remains on solving the Physician Gap through a physician-led advocacy approach that engages the entire healthcare ecosystem and enables a better healthcare experience for our members,” said Rajeev Singh, Accolade Chairman of the Board of Directors and Chief Executive Officer.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACCD:
- Notable companies reporting before tomorrow’s open
- Options Volatility and Implied Earnings Moves This Week, October 07 – October 11, 2024
- Is ACCD a Buy, Before Earnings?
- Starbucks picks new CEO, Baxter divests Kidney Care segment: Morning Buzz
- Accolade working with Morgan Stanley to explore sale, Dealreporter says